"Solifenacin Succinate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.
| Descriptor ID |
D000069464
|
| MeSH Number(s) |
D03.605.687.900 D03.633.100.531.820.594
|
| Concept/Terms |
Solifenacin Succinate- Solifenacin Succinate
- Succinate, Solifenacin
- Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
Solifenacin- Solifenacin
- 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
|
Below are MeSH descriptors whose meaning is more general than "Solifenacin Succinate".
Below are MeSH descriptors whose meaning is more specific than "Solifenacin Succinate".
This graph shows the total number of publications written about "Solifenacin Succinate" by people in this website by year, and whether "Solifenacin Succinate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Solifenacin Succinate" by people in Profiles.
-
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018 Jul; 117:50-56.
-
Medication effects on periurethral sensation and urethral sphincter activity. Female Pelvic Med Reconstr Surg. 2015 Mar-Apr; 21(2):77-82.
-
Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome. Int Urol Nephrol. 2012 Apr; 44(2):425-9.
-
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
-
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
-
Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.